How to buy Pluristem stock (PSTI)

Pluristem is a biotechnology business based in the US. Pluristem shares (PSTI) are listed on the NASDAQ and all prices are listed in US Dollars. Pluristem employs 153 staff and has a trailing 12-month revenue of around $234,000.

Our top picks for where to buy Pluristem stock

Buy Pluristem stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Pluristem stock price (NASDAQ: PSTI)

Use our graph to track the performance of PSTI stocks over time.

Pluristem shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$1.19
200-day moving average more info button	$1.76
Wall St. target price	$3.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.46

Is it a good time to buy Pluristem stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pluristem financials

Revenue TTM	$234,000
Gross profit TTM	$23,000
Return on assets TTM	-37.35%
Return on equity TTM	-86.55%
Profit margin	0%
Book value	$1.18
Market Capitalization more info button	$32.3 million

TTM: trailing 12 months

Pluristem share dividends

We're not expecting Pluristem to pay a dividend over the next 12 months.

Have Pluristem's shares ever split?

Pluristem's shares were split on a 1:10 basis on 24 July 2019 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pluristem shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pluristem shares which in turn could have impacted Pluristem's share price.

Pluristem share price volatility

Over the last 12 months, Pluristem's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pluristem's is 1.9127. This would suggest that Pluristem's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Pluristem overview

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions.

Frequently asked questions

What percentage of Pluristem is owned by insiders or institutions?
Currently 7.281% of Pluristem shares are held by insiders and 12.805% by institutions. How many people work for Pluristem?
Latest data suggests 153 work at Pluristem. When does the fiscal year end for Pluristem?
Pluristem's fiscal year ends in June. Where is Pluristem based?
Pluristem's address is: Building No. 5, Haifa, Israel, 3508409 What is Pluristem's ISIN number?
Pluristem's international securities identification number is: US72940R3003 What is Pluristem's CUSIP number?
Pluristem's Committee on Uniform Securities Identification Procedures number is: 72940R300